Literature DB >> 23775974

CYP2D6 genotype should not be used for deciding about tamoxifen therapy in postmenopausal breast cancer.

James M Rae, Meredith Regan, Brian Leyland-Jones, Daniel F Hayes, Mitch Dowsett.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23775974     DOI： 10.1200/JCO.2013.49.4278

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  4 in total

1.  Re: Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA.

Authors:  Matthew P Goetz; Hiltrud Brauch; Mark J Ratain; Nancy J Cox; Yusuke Nakamura; Richard Weinshilboum; James N Ingle
Journal:  J Natl Cancer Inst       Date:  2014-04-03       Impact factor: 13.506

2.  Population pharmacokinetic modelling to assess the impact of CYP2D6 and CYP3A metabolic phenotypes on the pharmacokinetics of tamoxifen and endoxifen.

Authors:  Rob ter Heine; Lisette Binkhorst; Anne Joy M de Graan; Peter de Bruijn; Jos H Beijnen; Ron H J Mathijssen; Alwin D R Huitema
Journal:  Br J Clin Pharmacol       Date:  2014-09       Impact factor: 4.335

Review 3.  Status of adjuvant endocrine therapy for breast cancer.

Authors:  Gaia Schiavon; Ian E Smith
Journal:  Breast Cancer Res       Date:  2014       Impact factor: 6.466

4.  Clinical Application of Pharmacogenetics: Where are We Now?

Authors:  Ron Hn van Schaik
Journal:  EJIFCC       Date:  2013-02-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.